3 assets in Bladder Small Cell Carcinoma

Therapeutic assets addressing Bladder Small Cell Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Atezolizumab Bladder Small Cell Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Lurbinectedin Bladder Small Cell Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Avelumab Bladder Small Cell Carcinoma	National Cancer Institute (NCI)	P2	CCC (48)